Recce Pharmaceuticals Announces Positive Data on Bactericidal Activity of RECCE® 327 Against All Six ESKAPE Pathogens
May 04, 2021 08:00 ET | Recce Pharmaceuticals
Highlights: More than 99.9% effective against full suite of ESKAPE pathogens, within hours of exposure to RECCE® 327 (R327) in independent bacterial efficacy studiesR327 remains effective against...
Recce Pharmaceuticals Announces Positive Data Against Streptococcus pneumoniae Sinusitis Infection in Animal Model
April 01, 2021 08:00 ET | Recce Pharmaceuticals
Highlights: Positive sinusitis infection data indicated in animal study Study supports broad spectrum potential of Recce’s anti-infective compounds against Streptococcus pneumoniae (S. pneumoniae)...
Recce Pharmaceuticals Announces The Pew Charitable Trusts' Addition of Recce’s Lead Compound RECCE® 327 to List of Antibiotic Treatments in Clinical Development
March 15, 2021 08:00 ET | Recce Pharmaceuticals
Highlights: RECCE® 327 included in The Pew Charitable Trusts’ annual assessment of non-traditional antibiotic treatment in clinical developmentRECCE® 327 is the only synthetic polymer drug candidate...
RECCE MASTER LOGO RGB - online.jpg
Recce Pharmaceuticals Dual Lists on Frankfurt Stock Exchange
March 09, 2021 08:00 ET | Recce Pharmaceuticals
Shares now trading on major German Trading Exchanges Shares trade under code: R9QNo related capital raising - trade of existing securities with trade volume to increase on Australian Stock Exchange...
RECCE MASTER LOGO RGB - online.jpg
Recce Pharmaceuticals Applies for Dual Listing on FSE (Frankfurt Stock Exchange)
February 24, 2021 08:00 ET | Recce Pharmaceuticals
Highlights: Broadens institutional and retail investor base across EU and enables access to additional capital markets No related capital raising - trade of existing securities with trade...
RECCE MASTER LOGO RGB - online.jpg
Recce Pharmaceuticals Announces Agreement with Fiona Stanley Hospital for a Phase 1/2 Clinical Trial Evaluating Topical Spray-On Antibiotic RECCE® 327 on Chronic Burn Wounds
February 16, 2021 08:00 ET | Recce Pharmaceuticals
Highlights: Phase I/II trial agreement with Fiona Stanley Hospital (Burns Unit) in Perth Western AustraliaStudy led by world leading burn treatment specialistsStudy will assess safety and efficacy of...
Recce Pharmaceuticals Announces Encouraging Results from Anti-viral Screening Program at The Doherty Institute Evaluating RECCE® 327 Against SARS-CoV-2
February 16, 2021 08:00 ET | Recce Pharmaceuticals
Highlights: RECCE® 327, a synthetic anti-infective 99.9% efficacious in confirmatory in-vitro screening assay against SARS-CoV-2 virusSARS-CoV-2 virus no longer detectable by virus titration at 4,000...
Recce Announces Positive Intranasal Animal Data against SARS-CoV-2 in International Study
December 23, 2020 08:00 ET | Recce Pharmaceuticals
Highlights: RECCE® 327 and RECCE® 529 demonstrated dose-dependent activity in-vivo against SARS-CoV-2 virus in Syrian golden hamsters, a well-accepted model of infection Intranasal administration of...
RECCE MASTER LOGO RGB - online.jpg
Recce Pharmaceuticals Provides Business Update
December 21, 2020 08:00 ET | Recce Pharmaceuticals
SYDNEY, Australia, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE), the Company developing new classes of synthetic anti-infectives, is pleased to provide an update on its...
RECCE MASTER LOGO RGB - online.jpg
Recce Pharmaceuticals Announces Anti-viral Patent Granted in Japan for RECCE® Anti-Infectives
November 23, 2020 08:00 ET | Recce Pharmaceuticals
SYDNEY, Australia, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE), the Company developing new classes of synthetic anti-infectives, is pleased to announce the Japan Patent...